Brief

BioLineRx’s Flagship Pancreas Cancer Drug Receives Orphan Drug Status in Europe

The clinical stage company’s drug received a similar designation in the U.S. last year

Nasdaq and Tel Aviv-listed BioLineRx Ltd. has received orphan drug designation from the European Medicines Agency (EMA) for its pancreatic cancer drug candidate, Motixafortide (BL-8040), the company announced Tuesday. BioLineRx’s drug received the same status from the U.S. Food and Drug Administration (FDA) in 2019. The clinical stage drug company was founded in 2003 and is currently traded at a market capitalization of $26.7 million.

 

BioLineRx CEO Philip Serlin. Photo: pr